Past Events
Nov 12, 2019 at 2:00 PM PST

Kodiak management will provide regulatory updates on the company’s “2022 Vision” for KSI-301 following from a successful FDA end-of-phase 2 meeting held on October 30, 2019, and discuss new data from its on-going Phase 1b clinical study of KSI-301 as well as other business highlights for the third quarter ended September 30, 2019.

Oct 12 - Oct 15, 2019

Retina Subspecialty Day: October 11-12, 2019
Friday, October 11, 2019
4:58pm PDT
Presentation by Charles C. Wykoff, MD, PhD

Extended Durability in Exudative Retinal Diseases Using the Novel Intravitreal Anti-VEGF Antibody Biopolymer Conjugate KSI-301: Results From the Phase 1b Study in Patients with wAMD, DME and RVO

San Francisco, CA
Sep 5 - Sep 8, 2019

Thursday, September 5, 2019
11:59am CEST
Presentation by Pravin U. Dugel, MD

Session: Novelties and Late Breaking Developments in Retina & Technology

Title: Novel anti-VEGF antibody biopolymer conjugate KSI-301 with potential for extended durability in retinal vascular diseases: first-time results from a phase 1b study in patients with wAMD, DME and RVO


Sunday, September 8, 2019
9:48am CEST
Presentation by Pravin U. Dugel, MD

Free Paper Session

Title: Extended durability in exudative retinal diseases using a new class of molecules: novel anti-VEGF antibody biopolymer conjugate KSI-301: first-time results of the phase 1b study in patients with wAMD, DME and RVO

Paris, France
Jul 26 - Jul 30, 2019

Saturday, July 27, 2019

11:48am CDT

Presentation by Pravin U. Dugel, MD

Antibody Biopolymer Conjugates: A Novel Scientific Approach and Platform for Extended-Durability Retinal Medicines - First Results from a Phase 1b Proof of Concept Study of KSI-301, an anti-VEGF ABC

Chicago, IL